The potential of plant-made vaccines to fight picornavirus

References

• Zell R, Delwart E, Gorbalenya AE, et al. ICTV virus taxonomy profile: picornaviridae. J Gen Virol. 2017;98(10):2421–2422. .
   PubMed Web of Science ®Google Scholar
• Anastasina M, Domanska A, Palm K, et al. Human Picornaviruses associated with neurological diseases and their neutralization by antibodies. J Gen Virol. 2017;98(6):1145–1158.
   PubMed Web of Science ®Google Scholar
• Lakshmi PS, Verma D, Yang X. Low cost tuberculosis vaccine antigens in capsules: expression in chloroplasts, bio-encapsulation, stability and functional evaluation in vitro. PLoS One. 2013;8(1):e54708.
   PubMed Web of Science ®Google Scholar
• Rosales-Mendoza S, Salazar-González JA. Immunological aspects of using plant cells as delivery vehicles for oral vaccines. Expert Rev Vaccines. 2014;13(6):737–749.
   PubMed Web of Science ®Google Scholar
• Pillet S, Aubin É, Trépanier S, et al. Humoral and cell-mediated immune responses to H5N1 plant-made virus-like particle vaccine are differentially impacted by alum and GLA-SE adjuvants in a Phase 2 clinical trial. NPJ Vaccines. 2018;3:3.
   PubMed Web of Science ®Google Scholar
• Zimran A, Dinur T, Revel-Vilk S, et al. Improvement in bone marrow infiltration in patients with type I Gaucher disease treated with taliglucerase alfa. J Inherit Metab Dis. 2018;41(6):1259–1265.
   PubMed Web of Science ®Google Scholar
• Choi BH, Kim DY. A national project to build a business support facility for plant-derived vaccine. Clin Exp Vaccine Res. 2019;8(1):1–3.
   PubMed Web of Science ®Google Scholar
• Rybicki EP. Plant-made vaccines and reagents for the One Health initiative. Hum Vaccin Immunother. 2017;13(12):2912–2917.
   PubMed Web of Science ®Google Scholar
• Shaaltiel Y, Bartfeld D, Hashmueli S, et al. Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher’s disease using a plant cell system. Plant Biotechnol J. 2007;5(5):579–590.
   PubMed Web of Science ®Google Scholar
• Qiu X, Wong G, Audet J, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014;514(7520):47–53.
   PubMed Web of Science ®Google Scholar
• Pillet S, Aubin É, Trépanier S, et al. A plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T cell response in healthy adults. Clin Immunol. 2016;168:72–87.
   PubMed Web of Science ®Google Scholar
• Schillberg S, Raven N, Fischer R. Twyman RM and Schiermeyer A. Molecular farming of pharmaceutical proteins using plant suspension cell and tissue cultures. Curr Pharm Des. 2013;19:5531–5542.
   PubMed Web of Science ®Google Scholar
• Ooi M, Wong SC, Lewthwaite P, et al. Clinical features, diagnosis and management of enterovirus 71. Lancet Neurol. 2010;9(11):1097–11105.
   PubMed Web of Science ®Google Scholar
• Ho M, Chen ER, Hsu KH, et al. An epidemic of enterovirus 71 infection in Taiwan. Taiwan enterovirus epidemic working group. N Engl J Med. 1999;341(13):929–935.
   PubMed Web of Science ®Google Scholar
• Zhang J, Sun J, Chang Z, et al. Characterization of hand, foot, and mouth disease in China between 2008 and 2009. Biomed Environ Sci. 2011;24(3):214–221.
   PubMed Web of Science ®Google Scholar
• Tu PV, Thao NT, Perera D, et al. Epidemiologic and virologic investigation of hand, foot. And mouth disease, southern Vietnam, 2005. Emerg Infect Dis. 2007;13(11):1733–1741.
   PubMed Web of Science ®Google Scholar
• Mao QY, Wang Y, Bian L, et al. EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD). Expert Rev Vaccines. 2016;15(5):599–606.
   PubMed Web of Science ®Google Scholar
• Chen HF, Chang MH, Chiang BL, et al. Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71. Vaccine. 2006;24(15):2944–2951.
   PubMed Web of Science ®Google Scholar
• Rweyemamu M, Roeder P, MacKay D, et al. Planning for the progressive control of foot-and-mouth disease worldwide. Transbound Emerg Dis. 2008;55(1):73–87.
   PubMed Web of Science ®Google Scholar
• OIE, 2017. Food-and-mouth disease, Colombia. [cited 11 October 2018].
   Google Scholar
• Knowles NJ, Wadsworth J, Reid SM, et al. Foot and mouth disease virus serotype A in Egypt. Emerg Infect Dis. 2007;13(10):1593–1596.
   PubMed Web of Science ®Google Scholar
• Adhikari G, Acharya KP, Upadhyay M, et al. Outbreak investigations of foot and mouth disease virus in Nepal between 2010 and 2015 in the context of historical serotype occurrence. Vet Med Sci. 2018;4(4):304–314.
   PubMed Web of Science ®Google Scholar
• Doel TR. FMD vaccines. Virus Res. 2003;91(1):81–99.
   PubMed Web of Science ®Google Scholar
• De Los Santos T, Diaz-San Segundo F, Rodriguez LL. The need for improved vaccines against foot-and-mouth disease. Curr Opin Virol. 2018;29:16–25.
   PubMed Web of Science ®Google Scholar
• Carrillo C, Wigdorovitz A, Oliveros JC, et al. Protective immune response to Foot-and-Mouth disease virus with VP1 expressed in transgenic plants. J Virol. 1998;72(2):1688–1690.
   PubMed Web of Science ®Google Scholar
• Wigdorovitz A, Pérez-Filgueira DM, Robertson N, et al. Protection of mice against challenge with Foot and Mouth Disease Virus (FMDV) by immunization with foliar extracts from plants infected with recombinant tobacco mosaic virus expressing the FMDV structural protein VP1. Virology. 1999;264(1):85–91.
   PubMed Web of Science ®Google Scholar
• Carrillo C, Wigdorovitz A, Trono K, et al. Induction of a virus-specific antibody response to Foot and Mouth disease virus using the structural protein VP1 expressed in transgenic potato plants. Viral Immunol. 2001;14(1):49–57.
   PubMed Web of Science ®Google Scholar
• Dus Santos MJ, Wigdorovitz A, Trono K, et al. A novel methodology to develop a foot and mouth disease virus (FMDV) peptide-based vaccine in transgenic plants. Vaccine. 2002;20(7–8):1141–1147.
   PubMed Web of Science ®Google Scholar
• He DM, Qian KX, Shen GF, et al. Stable expression of foot-and-mouth disease virus protein VP1 fused with cholera toxin B subunit in the potato (Solanum tuberosum). Colloids Surf B Biointerfaces. 2007;55(2):159–163.
   PubMed Web of Science ®Google Scholar
• Rao JP, Agrawal P, Mohammad R, et al. Expression of VP1 protein of serotype A and O of foot-and-mouth disease virus in transgenic sunnhemp plants and its immunogenicity for guinea pigs. Acta Virol. 2012;56(2):91–99.
   PubMed Web of Science ®Google Scholar
• Huang Y, Liang W, Wang Y, et al. Immunogenicity of the epitope of the Foot-and-Mouth disease virus fused with a hepatitis B core protein as expressed in transgenic tobacco. Viral Immunol. 2005;18(4):668–677.
   PubMed Web of Science ®Google Scholar
• Yang CD, Liao JT, Lai CY, et al. Induction of protective immunity in swine by recombinant bamboo mosaic virus expressing foot-and-mouth disease virus epitopes. BMC Biotechnol. 2007;7:62.
   PubMed Web of Science ®Google Scholar
• Andrianova EP, Krementsugskaia SR, Lugovskaia NN, et al. Foot and mouth disease virus polyprotein protein produced in bacteria and plants induces protective immunity in guinea pigs. Biochemistry. 2011;76(3):339–346.
   PubMed Web of Science ®Google Scholar
• Dus Santos MJ, Carrillo C, Ardila F, et al. Development of transgenic alfalfa plants containing the foot and mouth disease virus structural polyprotein gene P1 and its utilization as an experimental immunogen. Vaccine. 2005;23(15):1838–1843.
   PubMed Web of Science ®Google Scholar
• Pan L, Zhang Y, Wang Y, et al. Foliar extracts from transgenic tomato plants expressing the structural polyprotein, P1-2A, and protease, 3C, from foot-and-mouth disease virus elicit a protective response in guinea pigs. Vet Immunol Immunopathol. 2008;121(1–2):83–90.
   PubMed Web of Science ®Google Scholar
• Wang Y, Shen Q, Jiang Y, et al. Immunogenicity of foot-and-mouth disease virus structural polyprotein P1 expressed in transgenic rice. J Virol Methods. 2012;181(1):12–17.
   PubMed Web of Science ®Google Scholar
• Veerapen VP, van Zyl AR, Wigdorovitz A, et al. Novel expresión of immunogenic foot-and-mouth disease virus-like particles in Nicotiana benthamiana. Virus Res. 2018;244:213–217.
   PubMed Web of Science ®Google Scholar
• Ruiz V, Beztarrica J, Rybicki EP, et al. Minimally processed crude leaf extracts of Nicotiana benthamiana containing recombinant foot and mouth disease virus-like particles are immunogenic in mice. Biotechnol Rep (Amst). 2018;20:e00283.
   PubMedGoogle Scholar
• R Dr Z, Gorbalenya AE, Hovi T, et al. ICTV taxonomic proposal 2016.009aS.A.v2.Hepatovirus_8sp. Create 8 species in the genus hepatovirus, family picornaviridae, order picornavirales; 2016.
   Google Scholar
• WHO. WHO position paper on hepatitis A vaccines`: june 2012- recommendations. Vaccine. 2013;31(2):285–286.
   PubMed Web of Science ®Google Scholar
• Lemom SM, Jordis JO, Van Damme P, et al. Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention. J Hepatol. 2018;68(1):167–184.
   Web of Science ®Google Scholar
• Chung HY, Lee HH, Kim KI, et al. Expression of a recombinant chimeric protein of hepatitis A virus VP1-Fc using a replicating vector based on Beet curly top virus in tobacco leaves and its immunogenicity in mice. Plant Cell Rep. 2011;30(8):1513–1521.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Poliomyelitis. [accessed 5 March 2019].
   Google Scholar
• Global Polio Erradication Initiative. Who are we. [accessed 2019 Jan 16].
   Google Scholar
• Fujiyama K, Saejung W, Yanagihara I, et al. In Planta production of immunogenic poliovirus peptide using tobacco mosaic virus-based vector system. J Biosci Bioeng. 2006;101(5):398–402.
   PubMed Web of Science ®Google Scholar
• Chan HT, Xiao Y, Weldon WC, et al. Cold chain and virus-free chloroplast-made booster vaccine to confer immunity against different poliovirus serotypes. Plant Biotechnol J. 2016;14(11):2190–2200.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Daniell H. Long-term evaluation of mucosal and systemic immunity and protection conferred by different polio booster vaccines. Vaccine. 2017;35(40):5418–5425.
   PubMed Web of Science ®Google Scholar
• Daniell H, Rai V, Xiao Y. Cold chain and virus-free oral polio booster vaccine made in lettuce chloroplast confers protection against all three poliovirus serotypes. Plant Biotechnol J. 2019;17(7):1357–1368.
   Google Scholar
• Marsian J, Fox H, Bahar MW, et al. Plant-made polio type 3 stabilized VLPs-a candidate synthetic polio vaccine. Nat Commun. 2017;8(1):245.
   PubMed Web of Science ®Google Scholar
• Rosales-Mendoza S, Nieto-Gómez R. Green therapeutic biocapsules: using plant cells to orally deliver biopharmaceuticals. Trends Biotechnol. 2018;36(10):1054–1067.
   PubMed Web of Science ®Google Scholar
• Global Polio Erradication Initiative. Endgame strategy plan. [accessed 03 February 2019].
   Google Scholar
• Hogle JM, Chow M, Filman DJ. Three-dimensional structure of poliovirus at 2.9 A resolution. Science. 1985;229(4720):1358–1365.
   PubMed Web of Science ®Google Scholar
• Noad R, Roy P. Virus-like particles as immunogens. Trends Microbiol. 2003;11(9):438–444.
   PubMed Web of Science ®Google Scholar
• Baldauf KJ, Royal JM, Hamorsky KT and Matoba N. Cholera toxin B: one subunit with many pharmaceutical applications. Toxins (Basel). 2015;7(3):974–996.
   PubMed Web of Science ®Google Scholar
• Boyaka PN. Inducing mucosal IgA: a challenge for vaccine adjuvants and delivery systems. J Immunol. 2017;199(1):9–16.
   PubMed Web of Science ®Google Scholar
• Gunasekaran B, Gothandam KM. A review on edible vaccines and their prospects. Braz J Med Biol Res. 2020;53(2):e8749.
   PubMed Web of Science ®Google Scholar
• Zahmanova GG, Mazalovska M, Takova KH, et al. Ravin NV and Lomonossoff GP. Rapid high-yield transient expression of swine Hepatitis E ORF capsid proteins in Nicotiana benthamiana plants and production of chimeric Hepatitis E virus like particles bearing the M2e Influenza epitope. Plants. 2019;24(9):1.
   Google Scholar
• Daniell H, Chan HT, Pasoreck EK. Vaccination via chloroplast genetics: affordable protein drugs for the prevention and treatment of inherited or infectious human diseases. Annu Rev Genet. 2016;50:595–618.
   PubMed Web of Science ®Google Scholar
• Takaiwa F, Wakasa Y, Takagi H, et al. Rice seed for delivery of vaccines to gut mucosal immune tissues. Plant Biotechnol J. 2015;13(8):1041–1055.
   PubMed Web of Science ®Google Scholar
• Su J, Zhu L, Sherman A, et al. Low cost industrial production of coagulation factor IX bioencapsulated in lettuce cells for oral tolerance induction in hemophilia B. Biomaterials. 2015;70:84–93.
   PubMed Web of Science ®Google Scholar
• Tekoah Y, Shulman A, Kizhner T, et al. Large-scale production of pharmaceutical proteins in plant cell culture-the Protalix experience. Plant Biotechnol J. 2015;13(8):1199–1208.
   PubMed Web of Science ®Google Scholar
• Fischer R, Holland T, Sack M, Schillberg S, et al. Glyco-engineering of plant-based expression systems. In: Advances in biochemical engineering/biotechnology. Berlin, Heidelberg: Springer; 2018. p. 1–30.
   Google Scholar
• Fischer R, Buyel JF. Molecular farming-The slope of enlightenment. Biotechnol Adv. 2020;16:107519.
   Web of Science ®Google Scholar
• FDA/USDA, 2002. Drugs, biologics and medical devices derived from bioengineered plants for use in humans and animals. Rockville, MD, USA: FDA; 2002.
   Google Scholar
• Kurup VM, Thomas J. Edible vaccines: promises and challenges. Mol Biotechnol. 2020;62(2):79–90.
   PubMed Web of Science ®Google Scholar